Jazz Pharmaceuticals' Lung Cancer Setback: Stock Impact
A late-stage setback for Jazz Pharmaceuticals' lung cancer drug Zepzelca rattled investors, but the larger story may ...
Choosing points over cash back can be beneficial in specific situations. Understand when to make that switch for better rewards.
27,195 articlesA late-stage setback for Jazz Pharmaceuticals' lung cancer drug Zepzelca rattled investors, but the larger story may ...
A Monday surge put Archer Aviation stock in the spotlight as investors reacted to major eVTOL news. This guide breaks...
A bold stake move in Hut 8 has sparked a new conversation about concentration, risk, and opportunity in crypto-relate...
Cathie Wood goes selling has people watching Ark Invest closely. This article breaks down three key trims, the reason...
A former lineman took a leap during the pandemic and built a $50 million knife company from a backyard workshop. The ...
As AI-driven growth reshapes tech investing, Goldman’s Future Tech Leaders ETF outperformed the S&P 500 in the first ...
A single metric may reveal whether Nvidia will continue dominate in AI. This deep dive explains the number, the risks...
A public image can swing earnings as fast as headlines. This article examines how scandals reshape money, plus concre...
A profitability-screened small-cap ETF is gaining attention as markets trend toward earnings power. The fund offers a...
A high-earning couple weighs a public-service run with a $34,000 pay cut, but Ramsey-trained finance logic says the r...
A spotlight on KNG shows it earns an 8.6% yield by selling covered calls on Dividend Aristocrats, but eight-year retu...
Investors targeting higher income are turning to closed-end funds trading at discounts to NAV, seeking a compelling y...